According to the Centers for Disease Control and Prevention, more than 40% of American adults have obesity, costing the U.S. healthcare system an estimated $173 billion annually. The development of incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), marks a major advance in obesity treatment. Registered Dietitian Nutritionists (RDNs) play a crucial role in providing medical nutrition therapy (MNT) to people using these medications as part of comprehensive obesity care.
Tune into this episode to learn about:
● the new paper published in JAND about injectable weight loss medications and lifestyle interventions
● the unique and evolving role of RDNs in obesity care
● why this new class of obesity medications has become so popular
● how these medications work
● the amount of weight loss needed to reduce obesity related comorbidities
● the evolution of different terms for these medications
● the pipeline of obesity medications we will see in the next few years
● how these medications have impacted the role of RDNs in counseling patients
● common side effects and nutritional considerations
● concerns about loss of muscle mass and bone density
● the importance of and role of exercise while taking these medications
● emotional aspects of significant weight loss in a short time
● how RDNs can be utilized in comprehensive obesity care in the long term
● how RDNs can stay informed and up to date on the medications and obesity care in general
● when people taking these medications should be referred to RDNs
● how working with an RDN can improve a person’s experience and outcomes
● additional information and resources for the public and health professionals
Full shownotes, transcript and resources: https://soundbitesrd.com/284)
